Physician profile
Emily Bennett Lucente
NPI 1720536964
$4,773.44
in general payments reported to CMS, 2019-2025
19 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $871 · 2023: $1,120 · 2024: $1,115 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Education: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.71 |
| Education | $466.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,678.08 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,194.07 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $500.31 | 2023-2024 | Dupixent |
| Genzyme Corporation | $388.42 | 2021-2025 | |
| Harmony Biosciences LLC | $315.17 | 2023-2025 | Wakix |
| Sanofi-Aventis U.S. LLC | $144.94 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.60 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $97.13 | 2023 | |
| Philips North America LLC | $60.02 | 2021 | |
| Genentech USA, INC. | $57.90 | 2023-2025 | Xolair |
| Inspire Medical Systems, INC. | $47.79 | 2023 | Inspire |
| Insmed, INC. | $31.20 | 2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $28.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.09 | 2024 | Quviviq |
| Verona Pharma, INC. | $20.05 | 2025 | Ohtuvayre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16.76 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $16.68 | 2025 | Auvelity |
| Amgen INC. | $15.57 | 2024 | Krystexxa |
| Abbvie INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Lucente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.